tiprankstipranks
Trending News
More News >
Longeveron’s Promising Alzheimer’s Treatment and Favorable Regulatory Developments Drive Buy Rating
PremiumRatingsLongeveron’s Promising Alzheimer’s Treatment and Favorable Regulatory Developments Drive Buy Rating
2M ago
Longeveron announces outcome of Type B meeting with FDA on Lomecel-B
Premium
The Fly
Longeveron announces outcome of Type B meeting with FDA on Lomecel-B
2M ago
Longeveron announces publication of results of Phase 2a trial of Lomecel-B
Premium
The Fly
Longeveron announces publication of results of Phase 2a trial of Lomecel-B
2M ago
Promising Outlook for Longeveron: ELPIS II Trial Progress and Financial Strength Highlighted
PremiumRatingsPromising Outlook for Longeveron: ELPIS II Trial Progress and Financial Strength Highlighted
2M ago
Longeveron Inc. Reports Strong 2024 Financial Growth
Premium
Company Announcements
Longeveron Inc. Reports Strong 2024 Financial Growth
2M ago
Longeveron reports Q4 revenue $700,000, consensus $637,500
Premium
The Fly
Longeveron reports Q4 revenue $700,000, consensus $637,500
2M ago
Longeveron initiated with a Buy at Roth MKM
PremiumThe FlyLongeveron initiated with a Buy at Roth MKM
5M ago
Longeveron initiated with a Buy at Roth MKM
Premium
The Fly
Longeveron initiated with a Buy at Roth MKM
5M ago
Longeveron reports Q3 EPS (34c), consensus (44c)
Premium
The Fly
Longeveron reports Q3 EPS (34c), consensus (44c)
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100